Cargando…
No advantage of laser-assisted over conventional intracytoplasmic sperm injection: a randomized controlled trial [NCT00114725]
BACKGROUND: Intracytoplasmic sperm injection (ICSI) is a component of infertility treatment often employed when conventional in vitro fertilization is unlikely to be successful. Despite good clinical results with ICSI, the procedure is typically associated with degeneration of a significant percenta...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550249/ https://www.ncbi.nlm.nih.gov/pubmed/16822317 http://dx.doi.org/10.1186/1743-1050-3-5 |
_version_ | 1782129212044345344 |
---|---|
author | Richter, Kevin S Davis, Alana Carter, Jennifer Greenhouse, Stephen J Mottla, Gilbert L Tucker, Michael J |
author_facet | Richter, Kevin S Davis, Alana Carter, Jennifer Greenhouse, Stephen J Mottla, Gilbert L Tucker, Michael J |
author_sort | Richter, Kevin S |
collection | PubMed |
description | BACKGROUND: Intracytoplasmic sperm injection (ICSI) is a component of infertility treatment often employed when conventional in vitro fertilization is unlikely to be successful. Despite good clinical results with ICSI, the procedure is typically associated with degeneration of a significant percentage (approximately 10%) of the treated oocytes. The cause of this degeneration remains unclear. Speculation that damage caused by oocyte compression during the injection procedure may be responsible has led to the development of a novel technique known as laser-assisted ICSI. This procedure involves drilling a small hole through the zona pellucida with a laser prior to sperm injection. Preliminary studies have suggested that laser-assisted ICSI may dramatically reduce oocyte degeneration rates. The objective of this study was to examine whether the reported benefits of laser-assisted ICSI could be verified on a larger, less-selected group of patients. METHODS: Oocytes retrieved from 59 patients scheduled for ICSI were randomly divided into equal treatment and control groups. Oocytes in the treatment group were inseminated by laser-assisted ICSI, while oocytes in the control group were inseminated by conventional ICSI. Outcome variables (oocyte fertilization and degeneration, embryo cell numbers and fragmentation on days 2 and 3, and compaction and blastocyst formation rates) were compared between treatment and control groups by paired-sample t-test. Subgroup analysis was performed according to zona pellucida and oolemma breakage patterns. RESULTS: No significant differences between treatment and control groups were observed for any of the measured outcome variables. However, fragile zonae pellucidae were associated with significantly poorer embryo quality, and fragile oolemmas that broke easily upon insertion of the injection needle were associated with a significantly higher oocyte degeneration rate. Nevertheless, there were also no between-treatment differences in clinical outcomes within these patient subpopulations. CONCLUSION: Contrary to previous reports based on smaller sample sizes, the results of this study suggest that there is no benefit of laser-assisted ICSI, either for the general population of ICSI patients, or for patients prone to zona pellucida or oolemma fragility. |
format | Text |
id | pubmed-1550249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-15502492006-08-17 No advantage of laser-assisted over conventional intracytoplasmic sperm injection: a randomized controlled trial [NCT00114725] Richter, Kevin S Davis, Alana Carter, Jennifer Greenhouse, Stephen J Mottla, Gilbert L Tucker, Michael J J Exp Clin Assist Reprod Research BACKGROUND: Intracytoplasmic sperm injection (ICSI) is a component of infertility treatment often employed when conventional in vitro fertilization is unlikely to be successful. Despite good clinical results with ICSI, the procedure is typically associated with degeneration of a significant percentage (approximately 10%) of the treated oocytes. The cause of this degeneration remains unclear. Speculation that damage caused by oocyte compression during the injection procedure may be responsible has led to the development of a novel technique known as laser-assisted ICSI. This procedure involves drilling a small hole through the zona pellucida with a laser prior to sperm injection. Preliminary studies have suggested that laser-assisted ICSI may dramatically reduce oocyte degeneration rates. The objective of this study was to examine whether the reported benefits of laser-assisted ICSI could be verified on a larger, less-selected group of patients. METHODS: Oocytes retrieved from 59 patients scheduled for ICSI were randomly divided into equal treatment and control groups. Oocytes in the treatment group were inseminated by laser-assisted ICSI, while oocytes in the control group were inseminated by conventional ICSI. Outcome variables (oocyte fertilization and degeneration, embryo cell numbers and fragmentation on days 2 and 3, and compaction and blastocyst formation rates) were compared between treatment and control groups by paired-sample t-test. Subgroup analysis was performed according to zona pellucida and oolemma breakage patterns. RESULTS: No significant differences between treatment and control groups were observed for any of the measured outcome variables. However, fragile zonae pellucidae were associated with significantly poorer embryo quality, and fragile oolemmas that broke easily upon insertion of the injection needle were associated with a significantly higher oocyte degeneration rate. Nevertheless, there were also no between-treatment differences in clinical outcomes within these patient subpopulations. CONCLUSION: Contrary to previous reports based on smaller sample sizes, the results of this study suggest that there is no benefit of laser-assisted ICSI, either for the general population of ICSI patients, or for patients prone to zona pellucida or oolemma fragility. BioMed Central 2006-07-05 /pmc/articles/PMC1550249/ /pubmed/16822317 http://dx.doi.org/10.1186/1743-1050-3-5 Text en Copyright © 2006 Richter et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Richter, Kevin S Davis, Alana Carter, Jennifer Greenhouse, Stephen J Mottla, Gilbert L Tucker, Michael J No advantage of laser-assisted over conventional intracytoplasmic sperm injection: a randomized controlled trial [NCT00114725] |
title | No advantage of laser-assisted over conventional intracytoplasmic sperm injection: a randomized controlled trial [NCT00114725] |
title_full | No advantage of laser-assisted over conventional intracytoplasmic sperm injection: a randomized controlled trial [NCT00114725] |
title_fullStr | No advantage of laser-assisted over conventional intracytoplasmic sperm injection: a randomized controlled trial [NCT00114725] |
title_full_unstemmed | No advantage of laser-assisted over conventional intracytoplasmic sperm injection: a randomized controlled trial [NCT00114725] |
title_short | No advantage of laser-assisted over conventional intracytoplasmic sperm injection: a randomized controlled trial [NCT00114725] |
title_sort | no advantage of laser-assisted over conventional intracytoplasmic sperm injection: a randomized controlled trial [nct00114725] |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550249/ https://www.ncbi.nlm.nih.gov/pubmed/16822317 http://dx.doi.org/10.1186/1743-1050-3-5 |
work_keys_str_mv | AT richterkevins noadvantageoflaserassistedoverconventionalintracytoplasmicsperminjectionarandomizedcontrolledtrialnct00114725 AT davisalana noadvantageoflaserassistedoverconventionalintracytoplasmicsperminjectionarandomizedcontrolledtrialnct00114725 AT carterjennifer noadvantageoflaserassistedoverconventionalintracytoplasmicsperminjectionarandomizedcontrolledtrialnct00114725 AT greenhousestephenj noadvantageoflaserassistedoverconventionalintracytoplasmicsperminjectionarandomizedcontrolledtrialnct00114725 AT mottlagilbertl noadvantageoflaserassistedoverconventionalintracytoplasmicsperminjectionarandomizedcontrolledtrialnct00114725 AT tuckermichaelj noadvantageoflaserassistedoverconventionalintracytoplasmicsperminjectionarandomizedcontrolledtrialnct00114725 |